Loading...
•
Dec 31, 2019
Gilead Sciences Q4 2019 Earnings Report
Gilead Sciences' financial results for Q4 2019 were announced, with total revenues of $5.9 billion and diluted EPS of $2.12.
Key Takeaways
Gilead Sciences announced its Q4 and full year 2019 financial results. The total revenues for the fourth quarter of 2019 were $5.9 billion, and the net income was $2.7 billion, or $2.12 per diluted share.
Fourth Quarter Product Sales reached $5.8 billion.
Full Year 2019 Product Sales amounted to $22.1 billion.
Full Year 2019 Diluted EPS was $4.22 per share.
Full Year 2019 Non-GAAP Diluted EPS was $6.63 per share.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Gilead provided full year 2020 guidance, projecting product sales between $21.8 billion and $22.2 billion and diluted EPS between $6.05 and $6.45.
Positive Outlook
- Product Sales: $21,800 - $22,200 million
- Non-GAAP Product Gross Margin: 86% - 87%
- R&D Expenses: Mid-single digit percentage growth
- SG&A Expenses: Mid-single digit percentage growth
- Operating Income: $10,100 - $10,800 million
Challenges Ahead
- Effective Tax Rate: ~21%
- Diluted EPS: $6.05 - $6.45
- GAAP Diluted EPS: $5.15 - $5.55
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...